Association Between Interleukin 4 Gene Seventy-Base-Pair Variable Number of Tandem Repeats Polymorphism and Uterine Leiomyoma

AUTHORS

Saeedeh Salimi 1 , 2 , Milad Mohammadoo-Khorasani ORCID 1 , 2 , * , Lida Namazi 3 , Maryam moossavi 4 , Anoosh Naghavi 1 , 5 , Minoo Yaghmaei 3

1 Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, IR Iran

2 Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran

3 Department of Obstetrics and Gynecology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran

4 Department of Biology, University of Sistan and Baluchestan, Zahedan, IR Iran

5 School of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran

How to Cite: Salimi S, Mohammadoo-Khorasani M, Namazi L, moossavi M, Naghavi A, et al. Association Between Interleukin 4 Gene Seventy-Base-Pair Variable Number of Tandem Repeats Polymorphism and Uterine Leiomyoma, Gene Cell Tissue. 2014 ; 1(2):e19462. doi: 10.17795/gct-19462.

ARTICLE INFORMATION

Gene, Cell and Tissue: 1 (2); e19462
Published Online: June 1, 2014
Article Type: Research Article
Received: April 14, 2014
Revised: May 7, 2014
Accepted: May 17, 2014
Crossmark

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background: Uterine Leiomyoma (UL) is the most common gynecological tumor and a public health problem. Higher serum interleukin 4 (IL-4) level, as an anti-inflammatory cytokine that regulates TH1/TH2 cells balance, has been observed in the uterine cavity.

Objectives: The aim of this study was to investigate the association between IL4 gene variable number of tandem repeats (VNTR) polymorphism and the risk of UL in southeast of Iran.

Patients and Methods: We compared of 99 patients with UL with that of 102 healthy controls. The IL4 VNTR polymorphism was genotyped by gel electrophoresis after PCR amplification.

Results: There was no significant association between RP*1/RP*2 and RP*2/RP*2 genotypes and UL; however, a significant association between RP*2/RP*2 genotype and UL was found after adjustment for age (OR, 4; 95% CI, 1.3-12.4; and P = 0.015). The frequency of RP*2 allele was significantly higher in women with UL (OR, 1.9; 95% CI, 1.1-3.5; and P = 0.03).

Conclusions: The IL4 VNTR RP*2/RP*2 genotype could be an age-related risk factor for UL. Moreover, the frequency of RP*2 allele was significantly higher in women with UL.

Keywords

Leiomyoma Interleukin-4 Minisatellite Repeats Polymorphism, Genetic

Copyright © 2014, Zahedan University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

1. Background

Uterine leiomyoma (UL) or fibroid is a noncancerous tumor originating from the myometrium (1). ULs are the most common genital neoplasms in women and may be the most prevalent tumors in in their reproductive age (2, 3). The prevalence of UL is about 30% to 40% in women in reproductive age; it becomes symptomatic in near one-third of patients and is the most common indication for hysterectomy (4). Although the related pathophysiology and proliferative pathway of this disorder is not clear yet, several studies suggested that the genetic, hormonal, anthropometrical, and reproductive factors might play important roles in developing UL (5, 6). The epidemiological studies suggested that early menarche is associated with increasing risk of fibroids (7, 8). Similar to ovarian and breast cancer, ULs are estrogen dependent as estrogen induces cell proliferation in different tissues including uterus (9, 10). Some evidences suggested that cytokines might have a key role in development of ULs. Elevated levels of some cytokines such as interleukin 4 (IL-4) have been observed in uterine cavity of patients with UL in comparison with the normal uterus (11, 12). The human IL-4, which is mapped on the long arm of chromosome 5 (5q31- 33), is produced by CD4+ helper T cells (Th2 cells), basophils, and mast cells (13). IL-4 has cytotoxic and anti-tumor effects that inhibits induction of nitric oxide synthase and therefore, inhibits release of superoxide by macrophages (14). There are several specific single nucleotide polymorphisms (SNPs) and variable number of tandem repeats (VNTRs) in cytokine genes that could play major roles in genetic predisposition to some diseases and cancers. Recent investigations have revealed that some of these polymorphisms could alter the cytokines production levels (15). There is a 70-base-pair (bp) VNTR polymorphism in the third intron of the IL4 gene that may alter the expression level of this gene. Three alleles for the IL4 gene VNTR polymorphism have been reported: RP*1 allele, three repeats; RP*2 allele, two repeats; and RP*3 allele, four repeats. The RP*1 allele is more frequent than RP*2 allele and RP*3 allele is the rarest one, which has been observed in few populations (16). Investigations showed that RP*3 allele is associated with high production of IL-4 (17). There is only one published report concerning the association of IL4 gene VNTR polymorphism with UL development (18).

2. Objectives

In the present study, we aimed to assess the probable association between 70-bp VNTR polymorphism of the IL4 gene and the risk of UL in southeast of Iran.

3. Patients and Methods

3.1. Patients and Sample Collection

This case-control study included 99 premenopausal women with clinically diagnosed UL who had underwent myomectomy or hysterectomy in Ali-Ebne-Abitaleb Hospital, Zahedan, southeast Iran, between 2012 and 2013. UL was diagnosed by detailed ultrasound examination and was confirmed by histopathological examination after myomectomy or hysterectomy. The control group consisted of 102 premenopausal women who were referred for routine yearly check-up and performing the Pap smear test; the controls were matched with the patients for age, ethnicity, and body mass index (BMI). The absence of UL was determined in controls after detailed ultrasound examination. All samples collection were approved by Ethics Committee of Zahedan University of Medical Sciences.

3.2. DNA Analysis

The DNA analysis was performed in the Cellular and Molecular Research Center (Zahedan, Iran). The DNA was extracted from whole blood using the salting-out method. The 70-bp VNTR region of IL4 gene was analyzed by polymerase chain reaction (PCR) using two oligonucleotide primers: forward, 5'AGGCTGAAAGGGGGAAAGC-3′; and reverse, 5′CTGTTCACCTCAACTGCTCC-3 ′ (19). PCR was performed on a 25-μL final volume contained 25 pmol of each primer, 0.1 mmol of dNTP (Fermentas, Lithuania), 0.5 μg of genomic DNA, 1.5 mmol of MgCl, 2.5 μL of PCR buffer, and 1.5 unit of Taq DNA polymerase (Fermentas, Lithuania); the process was performed according to the following protocol: initial denaturation at 94℃ for five minutes; 30 cycles of denaturation at 94℃ for 50 seconds, annealing at 61℃ for 30 seconds; extension at 72℃ for 45 seconds; and final extension at 72℃ for five minutes. PCR products were separated by electrophoresis on a 1.5% agarose gel and were visualized by ethidium bromide staining (Figure 1).

Figure 1. Gel Electrophoresis With Ethidium Bromide Staining Demonstrating IL4 Genotype Variable Number of Tandem Repeats Polymorphism
Gel Electrophoresis With Ethidium Bromide Staining Demonstrating IL4 Genotype Variable Number of Tandem Repeats Polymorphism

Lane M, molecular maker (Gene ruler 50-bp DNA ladder plus); lanes 1, 2, 3, 4, 7, 9, 10, 11, and 12 RP*1/RP*1 genotype; lanes 5, 6, and 8 RP*1/RP*2 genotype; and lane 13 RP*2/RP*2 genotype.

3.3. Statistical Analysis

All statistical analyses were performed using the SPSS v.15.0 (SPSS Inc, Chicago IL, USA). Direct gene counting method was used to determine the allele frequency. The independent effect of the IL4 VNTR genotypes on UL was examined by logistic regression analysis. The odds ratio (OR) and 95% confidence intervals (CI) were also estimated. The χ2 test was used for deviation of genotype distribution from Hardy-Weinberg equilibrium. In all tests, P value less than 0.05 was considered statistically significant.

4. Results

The demographic data of patients with UL and control group are shown in Table 1. There were no significant differences in age, BMI, and marital status between two groups. No significant differences in menstrual history including age at menarche, duration of menses, and duration of the menstrual cycle were found between the control and patients. The frequency of bleeding and pain were significantly higher in patients than in controls (P < 0.0001). Deviation from the Hardy-Weinberg equilibrium for IL4 VNTR polymorphism was observed in neither patients nor controls (P > 0.05). The allelic and genotypic frequencies of IL4 VNTR polymorphism in patients and controls are shown in Table 2.

The frequency of RP*1/RP*1, RP*1/RP*2, and RP*2/RP*2 genotypes were respectively 70%, 24%, and 6% in patients with UL and respectively 80%, 19%, and 1% in controls. There were no significant differences in frequency of RP*1/RP*2 versus RP*1/RP*1 genotype between patients and controls, even after adjustment for age. Although the frequency of RP*2/RP*2 was not significantly higher than RP*1/RP*1 genotype in patients in comparison with the controls (OR, 2.7; 95% CI, 0.9-7.8; and P = 0.07), increased risk of UL was observed in individuals with RP*2/RP*2 genotype after adjustment for age (OR, 4; 95% CI, 1.3-12.4; and P = 0.015). The frequency of PR*2 allele were 18% and 10% in patients and healthy controls, respectively, which showed a significant difference (OR, 1.9; 95% CI, 1.1-3.5; P = 0.03).

Table 1. Demographic Data of Patients With Leiomyoma and Control Group a,b
Patients (n = 99)Controls (n = 102)P Value
Age, y38.5 ± 9.836.7 ± 5.5NS
Marriage statusNS
Married98100NS
Unmarried12NS
BMI, Kg/m225.3 ± 4.825.4 ± 4.7NS
Age at menarche, y13.1 ± 1.513.5 ± 1.1NS
Duration of menses, d6.6 ± 2.75.8 ± 1.5NS
Menstrual cycle, d28.6 ± 2.329.1 ± 3.4NS
Bleeding57 (58)6 (6)0.0001
Pain28 (28)8 (8)0.0001

a Abbreviations: BMI, body mass index; NS, not significant.

b Data are presented as mean ± SD or No. (%).

Table 2. Genotypes and Alleles Frequency of IL4 VNTR Polymorphism in Patients With Uterine Leiomyoma and Controls a,b
Genotype Patient (n = 99)Control (n = 102)P ValueOR (95% CI)P Value cOR (95% CI) d
RP*1/RP*169 (70)82 (80)Ref = 1Ref = 1
RP*1/RP*224 (24)19 (19)0.21.5 (0.8-3)0.11.8 (0.9-3.7)
RP*2/RP*26 (6)1 (1)0.072.7 (0.9-7.8)0.0154 (1.3-12.4)
Allele
RP*1162 (82)183 (90)Ref = 1--
RP*236 (18)21 (10)0.031.9 (1.1-3.5)--

a Abbreviations: CI, confidence interval; OR, odds ratio.

b Data are presented as No. (%).

c Adjusted P value for age.

d Adjusted OR for age.

5. Discussion

In this investigation we focused on the association of IL4 VNTR polymorphism with UL development in southeast of Iran. There was not any association between RP*1/RP*2 genotype of IL4 VNTR polymorphism and UL development even after adjustment for age. Although the frequency of RP*2/RP*2 genotype was not statistically higher than RP*1/RP*1 genotype in patients in comparison with the controls, the frequency was significantly higher after adjustment for age.

UL is the most prevalent noncancerous tumor in women. Although 75 out of 100 women have UL, only around 25% of patients present with its symptoms and signs (2). Several studies have suggested that UL arises from a single neoplastic smooth muscle of myometrium (20). Moreover, evidences have shown the association between serum levels of cytokines and UL development (18). Some studies showed that several cytokine genes polymorphism are associated with different cancers such as breast cancer (21), cervical cancer (22, 23), gastric cancer (23), hepatocellular carcinoma (24), and ovarian cancer (25, 26).

These observations supported the hypothesis that immunological, inflammatory, and anti-inflammatory processes could play key roles in tumor development (12). A few studies reviewed the association of IL4 SNPs with UL development and some of the studies indicated the association between these SNPs and UL (27). Recently, the association of IL4 VNTR polymorphism with several diseases such as cervical cancer (19), breast cancer (28), end-stage renal disease (29), systemic lupus erythematosus (30), oral cancer (31), preeclamsia (32) and multiple sclerosis (33) have been investigated. Shekari et al. showed that the frequency of RP*1/RP*2 genotype of IL4 VNTR polymorphism was significantly higher in patients with cervical cancer than healthy women, which is similar to our results (19). The correlation between IL1beta-511 promoter polymorphism and increased frequency of UL has been reported by Pietrowski et al. and Taghizade-Mortezaee et al. (34, 35). Moreover, Litovkin et al. showed a trend for association between IL6 -174C allele and developing UL (36). Sosna et al. reported that CC genotype of IL4 -590 C > T and -33 C > T polymorphisms were less frequent in patients with UL in comparison to the controls (27).

There is only one published report concerning the association between IL4 VNTR polymorphism and UL by Hsieh et al. in 2007 (18). Although they found a slight increase in the frequency of RP*1/RP*2 and RP*2/RP*2 genotypes in patients with UL in comparison with women without UL in Taiwan, the differences were not statistically significant, which is consistent with our results before adjustment for age. Moreover, the frequency of RP*2 allele in patients with UL was not significantly different from women without UL, which was similar to our results. Our study suffered from some limitations. Firstly, our sample size was small that could affect the results. Secondly, if we could perform the study on both myomatous and normal tissues, the results would be more valuable. To promote the knowledge concerning the role of IL4 VNTR polymorphism in UL pathogenesis, more extensive studies with larger numbers of people including other ethnic groups from the viewpoint of genetic and environmental factors should be performed.

In conclusion, there was an association between IL4 VNTR RP*2/RP*2 genotype and developing UL after adjustment for age; therefore, this genotype could be an age-related risk factor for UL. Moreover, the frequency of RP*2 allele was significantly higher in women with UL.

Acknowledgements

Footnotes

References

  • 1.

    Miller NF, Ludovici PP. On the origin and development of uterine fibroids. Am J Obstet Gynecol. 1955; 70(4) : 720 -40 [PubMed]

  • 2.

    Stewart EA. Uterine fibroids. Lancet. 2001; 357(9252) : 293 -8 [DOI][PubMed]

  • 3.

    Vollenhoven BJ, Lawrence AS, Healy DL. Uterine fibroids: A clinical review. Br J Obstet Gynaecol. 1990; 97(4) : 285 -98 [DOI][PubMed]

  • 4.

    Falcone T, Walters MD. Hysterectomy for benign disease. Obstet Gynecol. 2008; 111(3) : 753 -67 [DOI][PubMed]

  • 5.

    Ligon AH, Morton CC. Genetics of uterine leiomyomata. Genes Chromosomes Cancer. 2000; 28(3) : 235 -45 [PubMed]

  • 6.

    Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect. 2003; 111(8) : 1037 -54 [PubMed]

  • 7.

    Vollenhoven B. Introduction: the epidemiology of uterine leiomyomas. Baillieres Clin Obstet Gynaecol. 1998; 12(2) : 169 -76 [PubMed]

  • 8.

    Parazzini F, La Vecchia C, Negri E, Cecchetti G, Fedele L. Epidemiologic characteristics of women with uterine fibroids: a case-control study. Obstet Gynecol. 1988; 72(6) : 853 -7 [PubMed]

  • 9.

    Sumitani H, Shozu M, Segawa T, Murakami K, Yang HJ, Shimada K, et al. In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism. Endocrinology. 2000; 141(10) : 3852 -61 [DOI][PubMed]

  • 10.

    Sabbah M, Courilleau D, Mester J, Redeuilh G. Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. Proc Natl Acad Sci U S A. 1999; 96(20) : 11217 -22 [PubMed]

  • 11.

    Inagaki N, Ung L, Otani T, Wilkinson D, Lopata A. Uterine cavity matrix metalloproteinases and cytokines in patients with leiomyoma, adenomyosis or endometrial polyp. Eur J Obstet Gynecol Reprod Biol. 2003; 111(2) : 197 -203 [PubMed]

  • 12.

    Malyshkina AI, Posiseeva LV, Sotnikova NY, Antsiferova JS, Suvorkina EE, Arevadze IE. Local immunological markers of different rate of growth of uterine myoma. Russ J Immunol. 2002; 7(1) : 58 -62 [PubMed]

  • 13.

    Gyan BA, Goka B, Cvetkovic JT, Kurtzhals JL, Adabayeri V, Perlmann H, et al. Allelic polymorphisms in the repeat and promoter regions of the interleukin-4 gene and malaria severity in Ghanaian children. Clin Exp Immunol. 2004; 138(1) : 145 -50 [DOI][PubMed]

  • 14.

    Inanir A, Tural S, Yigit S, Kalkan G, Pancar GS, Demir HD, et al. Association of IL-4 gene VNTR variant with deep venous thrombosis in Behcet's disease and its effect on ocular involvement. Mol Vis. 2013; 19 : 675 -83 [PubMed]

  • 15.

    Kesarwani P, Ahirwar D, Singh R, Manchanda PK, Mittal RD. Do IL-4 intron 3 VNTR and IL-6 (-174) G/C variants reflect ethnic variation? A comparative study between the global and North Indian populations. Asian Pac J Cancer Prev. 2008; 9(1) : 76 -80 [PubMed]

  • 16.

    Mout R, Willemze R, Landegent JE. Repeat polymorphisms in the interleukin-4 gene (IL4). Nucleic Acids Res. 1991; 19(13) : 3763 [PubMed]

  • 17.

    Nakashima H, Miyake K, Inoue Y, Shimizu S, Akahoshi M, Tanaka Y, et al. Association between IL-4 genotype and IL-4 production in the Japanese population. Genes Immun. 2002; 3(2) : 107 -9 [DOI][PubMed]

  • 18.

    Hsieh YY, Chang CC, Tsai CH, Lin CC, Tsai FJ. Interleukin (IL)-12 receptor beta1 codon 378 G homozygote and allele, but not IL-1 (beta-511 promoter, 3953 exon 5, receptor antagonist), IL-2 114, IL-4-590 intron 3, IL-8 3'-UTR 2767, and IL-18 105, are associated with higher susceptibility to leiomyoma. Fertil Steril. 2007; 87(4) : 886 -95 [DOI][PubMed]

  • 19.

    Shekari M, Kordi-Tamandani DM, MalekZadeh K, Sobti RC, Karimi S, Suri V. Effect of anti-inflammatory (IL-4, IL-10) cytokine genes in relation to risk of cervical carcinoma. Am J Clin Oncol. 2012; 35(6) : 514 -9 [DOI][PubMed]

  • 20.

    Medikare V, Kandukuri LR, Ananthapur V, Deenadayal M, Nallari P. The genetic bases of uterine fibroids; a review. J Reprod Infertil. 2011; 12(3) : 181 -91 [PubMed]

  • 21.

    DeMichele A, Martin AM, Mick R, Gor P, Wray L, Klein-Cabral M, et al. Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res. 2003; 63(22) : 8051 -6 [PubMed]

  • 22.

    Chen X, Han S, Wang S, Zhou X, Zhang M, Dong J, et al. Interactions of IL-12A and IL-12B polymorphisms on the risk of cervical cancer in Chinese women. Clin Cancer Res. 2009; 15(1) : 400 -5 [DOI][PubMed]

  • 23.

    Mustea A, Sehouli J, Konsgen D, Stengel D, Sofroni D, Lichtenegger W. Interleukin 1 receptor antagonist (IL-1RA) polymorphism in women with cervical cancer. Anticancer Res. 2003; 23(2A) : 1099 -102 [PubMed]

  • 24.

    Hirankarn N, Kimkong I, Kummee P, Tangkijvanich P, Poovorawan Y. Interleukin-1beta gene polymorphism associated with hepatocellular carcinoma in hepatitis B virus infection. World J Gastroenterol. 2006; 12(5) : 776 -9 [PubMed]

  • 25.

    Bushley AW, Ferrell R, McDuffie K, Terada KY, Carney ME, Thompson PJ, et al. Polymorphisms of interleukin (IL)-1alpha, IL-1beta, IL-6, IL-10, and IL-18 and the risk of ovarian cancer. Gynecol Oncol. 2004; 95(3) : 672 -9 [DOI][PubMed]

  • 26.

    Lai KC, Chen WC, Jeng LB, Li SY, Chou MC, Tsai FJ. Association of genetic polymorphisms of MK, IL-4, p16, p21, p53 genes and human gastric cancer in Taiwan. Eur J Surg Oncol. 2005; 31(10) : 1135 -40 [DOI][PubMed]

  • 27.

    Sosna O, Kolesar L, Slavcev A, Skibova J, Fait T, Mara M, et al. Th1/Th2 cytokine gene polymorphisms in patients with uterine fibroid. Folia Biol (Praha). 2010; 56(5) : 206 -10 [PubMed]

  • 28.

    Konwar R, Chaudhary P, Kumar S, Mishra D, Chattopadhyay N, Bid HK. Breast cancer risk associated with polymorphisms of IL-1RN and IL-4 gene in Indian women. Oncol Res. 2009; 17(8) : 367 -72 [PubMed]

  • 29.

    Mittal RD, Manchanda PK. Association of interleukin (IL)-4 intron-3 and IL-6 -174 G/C gene polymorphism with susceptibility to end-stage renal disease. Immunogenetics. 2007; 59(2) : 159 -65 [DOI][PubMed]

  • 30.

    Wu MC, Huang CM, Tsai JJ, Chen HY, Tsai FJ. Polymorphisms of the interleukin-4 gene in chinese patients with systemic lupus erythematosus in Taiwan. Lupus. 2003; 12(1) : 21 -5 [PubMed]

  • 31.

    Tsai MH, Chen WC, Tsai CH, Hang LW, Tsai FJ. Interleukin-4 gene, but not the interleukin-1 beta gene polymorphism, is associated with oral cancer. J Clin Lab Anal. 2005; 19(3) : 93 -8 [DOI][PubMed]

  • 32.

    Salimi S, Mohammadoo-Khorasani M, Yaghmaei M, Mokhtari M, Moossavi M. Possible Association of IL-4 VNTR Polymorphism with Susceptibility to Preeclampsia. Biomed Res Int. 2014; 2014 : 497031 [DOI][PubMed]

  • 33.

    Karakus N, Yigit S, Kurt GS, Cevik B, Demir O, Ates O. Association of interleukin (IL)-4 gene intron 3 VNTR polymorphism with multiple sclerosis in Turkish population. Hum Immunol. 2013; 74(9) : 1157 -60 [DOI][PubMed]

  • 34.

    Pietrowski D, Thewes R, Sator M, Denschlag D, Keck C, Tempfer C. Uterine leiomyoma is associated with a polymorphism in the interleukin 1-beta gene. Am J Reprod Immunol. 2009; 62(2) : 112 -7 [DOI][PubMed]

  • 35.

    Taghizade-Mortezaee F, Hashemzadeh-Chaleshtori M, Kheiri S, Parvin N, Norbakhsh M, Etemadi S, et al. Association of Interleukin-1β (IL-1β) Gene Polymorphisms with Uterine Leiomyoma. Zahedan J Res Med Sci. 2012; 14(7) : 53 -6

  • 36.

    Litovkin KV, Domenyuk VP, Bubnov VV, Zaporozhan VN. Interleukin-6 -174G/C polymorphism in breast cancer and uterine leiomyoma patients: a population-based case control study. Exp Oncol. 2007; 29(4) : 295 -8 [PubMed]

  • COMMENTS

    LEAVE A COMMENT HERE: